Every Form 4 that Aligos Therapeutics, Inc. (ALGS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALGS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALGS filings page.
Aligos Therapeutics director Heather Preston received a new stock option grant. The award covers 5,860 shares of common stock with an exercise price of $5.50 per share and expires on June 25, 2036.
The option will vest and become exercisable in full on the earlier of the first anniversary of the June 25, 2026 grant date or immediately prior to the company’s 2027 annual stockholder meeting, provided she continues serving the company through that date.
Aligos Therapeutics director Margarita Chavez received a grant of stock options covering 5,860 shares of common stock. The options have an exercise price of $5.50 per share and expire on June 25, 2036.
According to the grant terms, all 5,860 options will vest and become exercisable as to 100% of the underlying shares on the earlier of the first anniversary of the June 25, 2026 grant date or immediately prior to Aligos Therapeutics' 2027 annual stockholder meeting, provided she continues to serve the company through that vesting date.
Aligos Therapeutics director Bridget A. Martell received a grant of 5,860 stock options to buy common shares at an exercise price of $5.50 per share. The options vest 100% on the earlier of the first anniversary of the grant date or immediately before the company’s 2027 annual stockholder meeting, contingent on continued service.
Aligos Therapeutics director James Paul Scopa received a new stock option grant covering 5,860 shares of common stock. The options have an exercise price of $5.50 per share and expire on June 25, 2036.
The grant vests and becomes fully exercisable as to 100% of the 5,860 shares on the earlier of the first anniversary of the grant date or immediately prior to Aligos Therapeutics' 2027 annual stockholder meeting, provided Scopa continues serving the company through that vesting date. This is a compensation-related award, not an open-market stock purchase or sale.
Aligos Therapeutics director Carole Nuechterlein received a new stock option grant. She was awarded options to purchase 5,860 shares of Aligos Therapeutics common stock at an exercise price of $5.50 per share. Following this grant, she holds options for 5,860 underlying shares.
According to the award terms, the options will vest and become exercisable for 100% of the 5,860 shares on the earlier of the first anniversary of the grant date or immediately prior to the company’s 2027 annual stockholder meeting, subject to her continuous service through the vesting date. The options are scheduled to expire on June 25, 2036.
Aligos Therapeutics director Peter Hirth received a stock option grant for 5,860 shares of common stock at an exercise price of $5.50 per share. The option vests in full on the earlier of the first anniversary of the grant date or immediately before the 2027 annual stockholder meeting, assuming continuous service, and expires in 2036.
Aligos Therapeutics reported that officer Julian A. Symons received a grant of stock options as part of his compensation. The award covers 23,310 stock options to buy Aligos common stock at an exercise price of $7.03 per share.
These options were granted on March 9, 2026 and vest over time. According to the terms, 1/48th of the options vest each month, starting from March 9, 2026, so that the entire grant becomes fully vested and exercisable on the fourth anniversary of that date, if he continues in service through each vesting date.
Aligos Therapeutics, Inc. principal accounting officer Nikhil Aneja received a grant of stock options covering 9,450 shares of common stock at an exercise price of $7.0300 per share. These options were awarded as compensation and do not represent an open-market purchase or sale.
According to the vesting terms, 1/48th of the total options vest in equal monthly installments starting on March 9, 2026, so all 9,450 options are scheduled to be fully vested and exercisable by the fourth anniversary of that vesting commencement date, contingent on continued service.
Aligos Therapeutics, Inc. reported a compensation-related stock option grant to officer Lesley Ann Calhoun. She was awarded options to acquire 37,485 shares of common stock at an exercise price of $7.03 per share, expiring on March 9, 2036.
According to the vesting terms, 1/48th of the options vest in equal monthly installments starting on March 9, 2026, so the grant becomes fully vested and exercisable on the fourth anniversary of that date, subject to her continued service. This filing reflects an acquisition of derivative securities, not an open-market purchase or sale of common shares.
Aligos Therapeutics, Inc. director and President & CEO Lawrence Blatt received a stock option grant covering 105,840 shares of common stock. The option has an exercise price of $7.03 per share and represents a right to buy, not a market purchase.
According to the vesting terms, 1/48th of the total shares vest in equal monthly installments starting on March 9, 2026, so the option becomes fully vested and exercisable on the fourth anniversary of that date, subject to his continued service. Following this award, he holds 105,840 stock option rights directly in this filing.